b9d2 Antibody

What is B9D2 and what cellular functions has it been implicated in?

B9D2 (B9 domain containing 2) is a protein with multiple cellular functions beyond its originally characterized role in cilia. Recent research has demonstrated that B9D2 plays significant roles in:

• Formation and maintenance of tight junctions between epithelial cells

• Establishment of epithelial cell polarity

• Regulation of epithelial barrier function

• Primary cilia formation and function

Studies have shown that B9D2 predominantly localizes at the plasma membrane between adjacent cells and near the nucleus in incompletely polarized cells. This membrane localization occurs upon cell contact establishment, coinciding with the formation of cell junctions. B9D2 co-localizes with ZO1 throughout epithelium formation and cell polarization .

Mutations in B9D2 have been associated with Meckel-Gruber syndrome and related disorders characterized by biliary dysgenesis, highlighting its importance in normal epithelial development and function .

What types of B9D2 antibodies are available for research applications?

Several types of B9D2 antibodies are available for research applications, with variations in host species, clonality, and reactivity. The main types include:

Most commercially available B9D2 antibodies are polyclonal and raised in rabbits, typically provided in unconjugated form at concentrations of approximately 0.1 mg/ml . These antibodies have been validated for various applications including immunohistochemistry (IHC), western blotting (WB), and enzyme-linked immunosorbent assay (ELISA) .

What are the common applications for B9D2 antibodies in research?

B9D2 antibodies are utilized in various research applications to study protein expression, localization, and function:

• Western Blotting (WB): For detecting and quantifying B9D2 protein levels in cell or tissue lysates. This technique is particularly useful for evaluating expression changes during development or in response to experimental treatments .

• Immunohistochemistry (IHC): For visualizing B9D2 protein localization in tissue sections, allowing researchers to examine its distribution across different cell types and subcellular compartments .

• Enzyme-Linked Immunosorbent Assay (ELISA): For quantitative detection of B9D2 in solution, providing a sensitive method to measure protein concentration .

• Immunofluorescence (IF): For high-resolution visualization of B9D2 localization in cells, particularly valuable for co-localization studies with other cellular proteins such as tight junction markers (ZO1, Claudin 4) to understand their spatial relationships .

Research demonstrates that IF applications have been especially informative for characterizing B9D2's punctiform distribution pattern at tight junctions and its dual localization to both tight junctions and primary cilia .

What species reactivity is available for B9D2 antibodies?

B9D2 antibodies exhibit reactivity against multiple species, making them versatile tools for comparative studies across different model organisms:

• Human

• Mouse

• Cow (Bovine)

• Dog (Canine)

• Guinea Pig

• Horse (Equine)

• Rabbit

• Rat

• Zebrafish (Danio rerio)

How should researchers validate B9D2 antibodies before experimental use?

Proper validation of B9D2 antibodies is critical for ensuring reliable experimental results. A comprehensive validation approach should include:

• Specificity Testing:

  • Western blot analysis showing a band of the expected molecular weight

  • Comparison of staining patterns between different antibodies targeting the same protein

  • Testing in B9D2 knockdown or knockout samples as negative controls

• Application-Specific Validation:

  • For IHC/IF: Confirmation of the expected subcellular localization pattern (at tight junctions and/or cilia)

  • For WB: Verification of appropriate band size and absence of non-specific bands

  • For ELISA: Standard curve analysis and determination of detection limits

• Cross-Reactivity Assessment:

  • Testing in multiple species if cross-reactivity is claimed

  • Evaluation in tissues known to express or not express B9D2

• Positive Controls:

  • Co-localization with known interaction partners (such as ZO1)

  • Comparison with published localization patterns

Research has demonstrated the importance of using shRNA-mediated B9D2 knockdown as a negative control, which revealed altered localization patterns of tight junction proteins and confirmed antibody specificity .

How does B9D2 localization change during epithelial cell polarization?

Research has revealed dynamic changes in B9D2 localization during epithelial cell polarization. In both cholangiocyte (NRC) and kidney epithelial (NRK) cell lines:

• Early Contact Phase: When cells begin to establish contacts, B9D2 predominantly localizes:

  • At the plasma membrane between adjacent cells

  • Near the nucleus in incompletely polarized cells

• Junction Formation Phase: As cell-cell contacts mature:

  • B9D2 co-localizes with ZO1 (tight junction marker)

  • The protein adopts a punctiform distribution along the cell junctions

  • B9D2 signals are spaced at approximately 300 nm intervals, distinct from the 500 nm spacing observed for Claudin 4

• Fully Polarized State: In confluent epithelial monolayers:

  • B9D2 maintains its localization at tight junctions

  • Upon ciliogenesis induction (through serum deprivation), B9D2 exhibits dual localization to both tight junctions and primary cilia

High-resolution microscopy has revealed precise positioning of B9D2 relative to other junction components:

• B9D2 and ZO1 overlap perfectly over a width of about 1 μm

• B9D2 and Claudin 4 immunostaining only partially overlap

• B9D2 appears closer to the cytosolic protein ZO1 than to the transmembrane protein Claudin 4

These findings indicate that B9D2 may serve as a structural or regulatory component in the cytoplasmic side of tight junctions during epithelial polarization, with potential additional functions at the ciliary base.

What is the role of B9D2 in tight junction structure and function?

B9D2 plays a crucial role in tight junction formation and integrity, as evidenced by knockdown experiments. When B9D2 expression is reduced using shRNA:

• Structural Changes in Tight Junctions:

  • ZO1 labeling becomes thicker (extending over 2 μm rather than 1 μm in control cells) and partially discontinuous

  • The ratio of membrane over juxtamembrane cytosolic fluorescent signals decreases, indicating less concentrated localization of junction proteins at the intercellular membrane

• Alterations in Junction Protein Localization:

  • Claudin 4 (tight junction protein) shows greatly reduced localization at cell junctions and becomes scattered over a larger zone around the intercellular membrane

  • E-cadherin (adherens junction protein) displays similar mislocalization patterns

  • β-catenin and Plakoglobin (other adherens junction components) remain relatively unchanged in their localization

• Functional Consequences:

  • Trans-Epithelial Resistance (TER) measurements show significant impairment of epithelial barrier function

  • Control epithelia show regular increases in TER values reaching more than 4000 ohms·cm², while B9D2 knockdown epithelia show compromised barrier integrity

These findings suggest that B9D2 functions as a critical organizer of tight junction architecture, particularly affecting the distribution of transmembrane components like Claudin 4. Its absence disrupts not only the structural organization of tight junctions but also their functional capacity to form a tight epithelial barrier.

How can researchers design optimal co-localization experiments to study B9D2's dual localization?

Optimizing experiments for studying B9D2's dual localization at tight junctions and cilia requires careful consideration of several factors:

• Cell Culture Conditions:

  • Cell density: Seed cells at varying densities to capture different stages of polarization

  • Timing: Culture NRC cells for 5 days or NRK cells for 1 day to reach appropriate confluence

  • Serum conditions: Maintain cultures with serum to keep ciliation rates below 5%, or induce ciliogenesis through serum deprivation in confluent monolayers

• Antibody Selection:

  • Choose antibodies validated for both tight junction and ciliary localization of B9D2

  • Consider polyclonal antibodies that may recognize multiple epitopes of the protein

  • Ensure compatibility with markers for tight junctions (e.g., ZO1) and cilia (e.g., acetylated tubulin)

• Imaging Strategy:

  • Use high-resolution confocal or super-resolution microscopy

  • Acquire z-stacks to capture both apical (ciliary) and lateral (junctional) structures

  • Implement multi-channel imaging to visualize B9D2 alongside junction and ciliary markers

• Quantification Approach:

  • Measure co-localization coefficients between B9D2 and junction/ciliary markers

  • Analyze the distribution pattern and spacing of B9D2 puncta at junctions (approximately 300 nm intervals)

  • Compare fluorescence intensity ratios of B9D2 at different subcellular locations

Research has demonstrated that maintaining cultures in the presence of serum kept the rate of ciliated cells below 5% in confluent monolayers, while serum deprivation induced ciliogenesis, allowing for the study of B9D2's dual localization under controlled conditions .

What methodological approaches can be used to investigate B9D2's role in epithelial barrier function?

Investigating B9D2's role in epithelial barrier function requires a multi-faceted experimental approach:

• Genetic Manipulation Strategies:

  • shRNA knockdown: Transfect cells with shRNA targeting B9D2 (with appropriate controls) to reduce protein expression

  • CRISPR/Cas9 gene editing: Generate complete knockout cell lines for more definitive functional studies

  • Rescue experiments: Re-express wild-type or mutant B9D2 in knockdown cells to identify critical domains

• Barrier Function Assays:

  • Trans-Epithelial Electrical Resistance (TER): Culture cells on permeable supports and measure electrical resistance across the monolayer over time

  • Experimental setup: Maintain transfected cells until confluence (typically 7 days), verify transfection efficiency (≥50%), then measure TER every hour for 4-5 days

  • Expected outcomes: Control cells should show regular increases in TER values (up to >4000 ohms·cm²), while B9D2-deficient cells exhibit compromised barrier development

• Tight Junction Protein Analysis:

  • Immunofluorescence: Visualize localization of junction proteins (ZO1, Claudin 4, E-cadherin) in B9D2-manipulated cells

  • Quantitative analysis: Calculate the ratio of membrane over juxtamembrane cytosolic fluorescent signals

  • Fluorescence profile analysis: Generate intensity profiles across junctions to measure junction width (typically 1 μm in control cells vs. 2 μm in B9D2 knockdown cells)

• Molecular Interaction Studies:

  • Co-immunoprecipitation to identify direct protein interactions between B9D2 and junction components

  • Proximity ligation assays to visualize protein-protein interactions in situ

  • Domain mapping to identify which regions of B9D2 are required for junction localization and function

This integrated approach connects molecular changes to functional outcomes when investigating B9D2's role in epithelial barrier integrity, as demonstrated in research where shRNA-mediated knockdown led to both structural alterations in tight junctions and measurable defects in barrier function .

How can computational approaches enhance the design of antibodies with specific binding profiles for B9D2?

Computational models offer powerful approaches for designing antibodies with customized specificity profiles for B9D2 epitopes:

• Biophysics-Informed Modeling:

  • Train models on data from experimentally selected antibodies

  • Associate distinct binding modes with each potential ligand/epitope

  • Enable prediction and generation of specific variants beyond those observed in experiments

• Experimental Data Collection and Analysis:

  • Conduct phage display experiments with antibody selection against diverse combinations of closely related B9D2 epitopes

  • Use high-throughput sequencing to analyze selected antibody populations

  • Verify that selection occurs primarily at the amino acid level rather than the nucleotide level

• Model Validation and Application:

  • Test the model's predictive power by using data from one ligand combination to predict outcomes for another

  • Generate antibody variants not present in the initial library that are specific to given combinations of epitopes

  • Experimentally validate model predictions to confirm specificity profiles

• Refinement Process:

  • Analyze potential biases in the experimental system (e.g., amplification bias)

  • Explore different parameterizations of binding modes to optimize model performance

  • Incorporate feedback from experimental validation to improve future predictions

The advantages of this approach for B9D2 antibody design include:

• Ability to discriminate between very similar epitopes

• Generation of antibodies with either high specificity for a particular target or cross-specificity for multiple defined targets

• Mitigation of experimental artifacts and biases in selection experiments

This combination of biophysics-informed modeling and experimental validation offers a powerful toolset for designing B9D2 antibodies with precisely tailored binding characteristics that can advance research into this protein's diverse cellular functions.